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Background: Rheumatoid arthritis (RA) is an inflammatory debilitating disease that 
affects the joints in the early and productive phases of an individual’s life. Several cyto-
kines have been linked to the disease pathogenesis and are known to contribute to the 
inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the 
pathogenesis of the disease has been already described as well as the identity of the 
genes that are regulated by this molecule, which are collectively known as the type I IFN 
signature. These genes have several functions associated with apoptosis, transcriptional 
regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. This article 
evaluated the expression of several genes of the IFN signature in different stages of 
disease and their correlation with the levels of anticitrullinated protein antibodies (ACPA) 
anticarbamylated protein (Anti-CarP) antibodies.
Methods: Samples from individuals with early and established RA, high-risk individ-
uals (ACPA+ and ACPA−), and healthy controls were recruited at “Unidad de Artritis 
y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. 
Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP 
determinations were made according to previously described protocols. RNA was 
isolated, and purity and integrity were determined according to RNA integrity number 
>6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs 
of the type I IFN signature. Relative gene expression was calculated according to Livak 
and Schmitgen.
results: Significant differences in gene expression were identified when comparing the 
different groups for MXA and MXB (P < 0.05), also when comparing established RA 
and ACPA− in both IFIT 1 and G15. An increased expression of ISG15 was identified 
(P < 0.05), and a clear tendency toward increase was identified for HERC5. EPSTRI1, 
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inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic, inflammatory, autoim-
mune disease that affects mainly the diarthrodial joints and is 
the cause of progressive and incapacitating joint destruction. 
Systemic manifestations are also present in individuals suffering 
from the disease, which can be classified as extraarticular mani-
festations. It is characterized by the presence of inflammatory 
immune cells in the joints. RA evolves toward a state of synovial 
hyperplasia, which is the cause of loss of bone structure and 
functional impairment. Several studies in North America and 
northern Europe show a prevalence of 0.5–1.1%, whereas in south 
of Europe, the reported prevalence is of 0.3–0.7%. Few studies 
have been performed in developing countries using the American 
College of Rheumatology 1987 criteria (1), showing a prevalence 
of 0.1–0.5%. However, it is difficult to establish whether this low 
prevalence is true or represents a referral bias due to the charac-
teristics of healthcare in developing countries (2).
Rheumatoid arthritis affects multiple dimensions of the quality 
of life of not only patients but also caregivers, such as the physical, 
emotional, affective and the economy of the family and the health 
care institutions, all of this accompanied of productivity loss (3). 
It has been estimated in Mexico that the financial burden of RA 
on the patient’s families is of 610 ± 302.2 USD/year, whereas the 
direct costs of RA for the health institutions is of 1,724.00 USD/
year/patient generating a great burden in the financial viability 
of public health care institutions (4). In addition, there is also an 
increased frequency in the use of biologics such as etanercept, 
infliximab, adalimumab, and rituximab, increasing significantly 
the cost of each patient’s treatment.
Several risk factors for RA have been identified, such as allelic 
variants of HLA-DR 01, 04, and others of the shared epitope (5). 
Also, several genes like the PAD4 or CTLA4 have been identified 
as independent risk factors for the disease (6). Modifiable risk 
factors such as smoking habits have been associated with severity 
of RA and with the presence of autoantibodies (7). Other diseases 
such as periodontal disease and gingivitis associated with several 
bacterial species such as PAD-like-producing Porphyromonas 
gingivalis have been speculated to increase the availability of cit-
rullinated antigens and therefore the probability of autoantibody 
generations against such antigens (8). Differences in age for the 
onset of RA and its symptoms have been proposed to be not only 
due to the exposure to UV radiation (9) but also due to pesticides, 
in both the domestic and work environments altering some 
mechanisms of the oxidative stress response and contributing to 
tissue damage and RA initiation (10).
The etiology of RA is complex; however, several components 
of the immune response have been linked to RA physiopathology 
(11). It has been described the important role of macrophages, 
dendritic cells, and neutrophils in joint inflammation and syno-
vial destruction in the initial phases of the disease, as the result of 
type I and II interferons (IFNs) activating myeloid cells and help-
ing to sustain the inflammatory process through the production 
of cytokines such as IL-6 and TNF-α (12). Synovial fibroblasts 
also contribute to this process due to increased responsiveness 
to inflammatory stimuli and reduced apoptosis, perpetuating 
it (13). Also, this inflammatory milieu and the increased avail-
ability of citrullinated and carbamylated antigens lead to the 
production of autoantibodies (14). Neutrophils contribute to 
the aforementioned process through the induction of RANK/
RANKL activation of osteoclasts, and this has been associated 
with an increased severity of RA (15). Khandpur et  al. have 
documented that neutrophils of RA patients are more prone 
to neutrophil extracellular trap formation, and given that these 
neutrophil-derived structures are rich in citrullinated antigens, 
they propose that these mechanisms are the ones responsible for 
autoantibody generation (16).
T cells, both CD4+ and CD8+ are also important actors in the 
inflammatory response in the synovia, the latter recently linked to 
increased citrullination through pore-forming mechanisms (17). 
In a similar fashion, the function of CD4+ Th2 lymphocytes has 
been suggested to be linked to autoantibody generation and to 
response polarization through interaction of CD40 and CD40L 
(18), as well as that mediated by OX-40 and OX40L (19) appear to 
have a preponderant role in autoantibody production, and these 
antibodies have an important role in the pathogenesis of disease 
(20). In the ACR/EULAR2010 criteria, anticitrullinated protein 
antibodies (ACPA) are considered an important tool to define 
the disease (21). The increase in ACPA levels is known to precede 
the onset of symptoms in first-degree relatives of RA patients, and 
there is also an increased risk of developing RA for the ACPA+ 
individuals (22). Recently, the presence of anticarbamylated pro-
tein (anti-CarP) has also been associated with RA severity and RA 
in undifferentiated arthralgia (23). This suggests that both ACPA 
and anti-CarP antibodies might have an important participation 
in the initiation of symptoms, in the early stages of the disease, 
IFI6, and IFI35 were found to be elevated in the chronic/established RA and early RA 
(P < 0.05). Significant correlations were identified for the IFN signature genes with the 
levels of ACPA and anti-CarP (P < 0.05).
conclusion: Our data confirm previous observations in the role of IFN signature and 
the pathogenesis of RA. Also, we provide evidence of an association between several 
genes of the IFN signature (that regulate Th2 cells and B cell proliferation) with the levels 
of anti-CarP antibodies and ACPA.
Keywords: rheumatoid arthritis, biomarkers, interferon-1 signature, anticarbamylated protein, anticitrullinated 
protein antibodies
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and also as markers of tolerance loss (23, 24). Moreover, it has 
been suggested that in the early stages of RA, type I IFNs might 
have an important role in the phenomenon of loss of tolerance, 
and in the chronic or established phase of RA, these molecules 
contribute to the perpetuation of the inflammatory response (25). 
Several of the type I IFN genes have been linked to antiviral and 
immunomodulatory activities (26). Type I IFNs induce dendritic 
cell maturation and the expression of both co-stimulatory and 
MHC I/II molecules as well as an increase in cytokine expres-
sion (27). Type I IFNs are produced mainly by plasmacytoid 
dendritic cells in response to a plethora of stimuli such as viral 
DNA and RNA or due to immune complexes of DNA/RNA 
antibody (28). IFN-α promotes dendritic cell differentiation and 
Th0 cell polarization to Th1 and also the cytotoxic response of 
CD8+ lymphocytes and NKT cells. It has also been described to 
induce B cell differentiation and antibody production and class 
switch to IgG (26). In RA, it has been described that immune 
complexes are produced due to an increased susceptibility to 
netosis of neutrophils (16), and also autoantibodies could be 
mediating this process acting as endogenous activators of IFN-α 
production (29). Although such mechanisms were first described 
for systemic lupus erythematosus (SLE) (30, 31), recent evidence 
suggest their participation in other autoimmune diseases such as 
RA (32). The genes activated through the described mechanism 
are known as IFN signature and comprise genes such as MXA and 
MXB associated with antiviral response (33, 34); IFIT1 and IFIT2 
linked to posttranscriptional regulation in viral infections (35); 
ISG15 and 55 as part of the proteasomal degradation machinery 
(36); LY6E and RSAD2 are involved in metabolism and prolif-
eration regulation of B  cells (37); also, EPSTRI1, IFI44L, and 
IFI35 (38) are thought to participate in IFN signature response 
modulation. IFI6 has been described to participate in apoptosis 
inhibition mediated by TRAIL (39).
In other autoimmune diseases such as SLE, the immune com-
plexes have been described to be internalized by pDC through 
the Fc-γRIIA into endosomes and interact with TLR7 and TLR9. 
After this activation, MyD88 induces activation and phospho-
rylation and translocation to the nucleus of the IFN-regulating 
factor 7 nuclear factor, inducing the transcription of the type I 
IFN genes (40).
Van der Pouw Kraan and colleagues identified several 
changes in gene expression in the IFN signature in established 
RA compared to control individuals (25), but the early stages 
of RA [early RA (eRA)] or the preclinical autoimmune phase 
of the disease was not the focus of that publication, and there 
are no available data regarding the role of the induced genes in 
these preclinical or early stages of the disease. Because of the 
direct association of several genes of the IFN signature with 
the physiopathology of RA, the natural history of the disease, and 
the expansion, regulation, and function of B cells, it is important 
to understand the relationship of the IFN signature activation 
and gene expression with the levels of ACPA and anti-CarP. The 
aims of this article were to analyze whether type I IFN-regulated 
genes were underexpressed or overexpressed in several groups of 
individuals at high risk of developing RA and in people with early 
or established disease and also to evaluate their relationship with 
autoantibodies in serum.
MaTerials anD MeThODs
Patients
The study participants were recruited between 2012 and 2014 at 
a Rheumatology Clinic in Guadalajara, Jalisco, Mexico, and at 
the “Emilio Varela Lujan” General Hospital of Zacatecas, Mexican 
Institute of Social Security (IMSS). Patients with eRA <2 years 
of symptoms without treatment (41) and chronic/established RA 
(cRA) with an evolution of >2  years and treated with disease-
modifying antirheumatic drugs (DMARD) were recruited. All 
study participants were evaluated by board-certified rheuma-
tologists, and diagnosis was confirmed or ruled out according 
to the 2010 revised European League Against Rheumatism/ACR 
criteria (42). Informed consent was obtained from all partici-
pants. This consent was approved by the local Ethics Committee 
(IMSS; R-2013-785-009). First-degree relatives of patients with 
confirmed RA were invited to participate in the study and were 
categorized into two groups: those negative (ACPA−) and 
positive (ACPA+) for ACPA. Unrelated healthy control (HC) 
subjects without self-reported history of autoimmune diseases, 
malignancy, or infectious diseases (HIV and HCV) were also 
enrolled. Blood samples were drawn for all subjects, and RNA 
later (Invitrogen) was used for RNA stabilization. Blood samples 
treated with RNA later and serum samples were stored at −20°C 
until use.
rna extraction, Quality control, and 
cDna synthesis
RNA isolation was performed according to a QIAamp protocol 
(Qiagen, Germany) adapted in our laboratory. Briefly whole 
blood samples that had been previously stabilized were unfrozen 
at room temperature and mixed vigorously in a 15-ml conical 
tube, and chloroform was added to the sample and subjected to 
centrifugation. The aqueous phase was transferred to another 
tube, and precipitation of RNA was made by means of ethanol. 
The mix was passed through a QIA-shredder spin column, and 
samples were processed as recommended by the supplier by 
another step of column purification and RNAse-free DNA diges-
tion in column. Elution of the purified RNA was made in RNAse-
free, diethyl pyrocarbonate (Sigma, St. Louis)-treated water. 
RNA integrity was assessed with the Bionalyzer 2100 (Agilent 
technologies, USA), and samples with RNA integrity number >6 
were used. The conversion of RNA to cDNA was made by means 
of the Superscript II reverse transcriptase kit (Invitrogen, USA), 
briefly, 2.5 μg of total RNA was retrotranscribed according to the 
manufacturers protocol in a Biometra Gradient model T ther-
mal cycler (Thermo Corp., Germany). cDNA was treated with 
DNAse-free RNAse H, and aliquots of cDNA at a concentration 
of 25 ng/μl were prepared for the qPCR assays.
gene expression analysis
Oligonucleotides and probes used in the qPCR assays were 
designed in the ROCHE Universal Probe Library. All assays were 
carried out in a Lightcycler 480 (ROCHE, USA) and with the light 
cycler Taqman Master kit (Roche, USA) with a cycling program 
as follows: preincubation 95°C/10 min, 45 cycles (denaturation 
TaBle 1 | Primer sequences for qPcr.
gene name/symbol Forward reverse accession number
IFIT1 gat gta tta cca cat ggg cag a tag cgg aag gga ttt gaa ag NM_001548.3
IFIT2 atc ccc cat cgc tta tct ct cca cct caa tta atc agg cac t NM_001547.4
IFI44L tgc taa gga gta tag cag atg acc ta cca caa cat cac tct cac ttt aag a NM_006820.2
ISG15 gag gca gcg aac tca tct tt agc atc ttc acc gtc agg tc NM_005101.3
MXA atc cag cca cca ttc caa caa caa gtt aaa tgg tat cac aga gc NM_002462.3
MXB ttc ttc aaa cac atc cat att tca cag tgg taa gtc ttt ctg cca gt NM_002463.1
EPSTRLI1 ccg gag aaa tga gat aca aag aat ggt gaa ccg gtt tag ctc tg NM_001002264.1
RSAD atg tga aag ccc aag gac ac ttt ggt ttc aaa taa cac tga ttg a NM_080657.4
HERC5 ctt cca gtg aaa gta tca tca agt g cca gag caa aat gct ttg att NM_016323.2
Ly6E atc ttc ttg cca gtg ctg ct gct tca gga agt aca gat tgc NM_002346.2
IFI6 tgc ttc tct tct ctc ctc caa gct ctc cga gca ctt ttt ctt NM_002038.3
IFI35 caa aag gag cac acg atc aa act caa ctg gct gga cat cat NM_005533.4
Hypoxanthine phosphoribosyltransferase tga cct tga ttt att ttg cat acc cga gca aga cgt tca gtc ct NM-000194.2
All assays were designed in the Universal Probe Library assay design center (ROCHE), and in silico tests were run for each pair of primers using the primer BLAST platform at NCBI.
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95°C/10s, Hyb 65°C/30s, and extension 70°C/1s), and cooling to 
40°C. From the amplification curves, Ct was obtained for each 
sample, for both the problem genes (Table  1; IFN signature 
genes) and the constitutive gene hypoxanthine phosphoribo-
syltransferase. Gene expression analysis was calculated with the 
2−ΔΔCt using the HC group as a reference.
acPa and anti-carP antibody 
Determinations
Serum samples collected from the participants were used for 
autoantibody (ACPA and Anti-CarP antibodies) measurements. 
Determination of anti-CCP2 antibodies was performed using 
enzyme-linked immunosorbent assays according to the manu-
facturer’s instructions (Euro-Diagnostica, Malmö, Sweden). 
The cutoff value for positivity was set at 25 arbitrary units/ml 
according to the suggestion of the manufacturer. Determination 
of anti-CarP was made as described before (43). The plates were 
incubated with carbamylated or uncarbamylated fetal calf serum 
(half plate each), washed with PBS/0.05% Tween (Sigma, USA), 
and subsequently blocked for 6 h at 4°C with 100 μl of PBS/1% 
BSA (Sigma, USA). After washing, the wells were incubated 
with 50  μl serum 1/50 diluted in PBS/1% BSA/0.05% Tween. 
Antibodies were detected using horseradish peroxidase (HRP)-
conjugated rabbit anti-human Ig antibody (ABCAM, UK), and 
HRP-conjugated HRP enzyme activity was visualized using 
ABTS (PeproTech, UK). As a standard, serial dilutions of a pooled 
serum sample from a patient with RA were used.
statistical analysis
Normality of data was assessed by a D’Agostino-Pearson nor-
mality test. According to data distribution, the multiple com-
parisons tests were performed: Kruskal–Wallis test with Dunn 
post hoc test was used for non-normally distributed data and the 
parametric one-way ANOVA with Tukey post hoc test, for the 
normally distributed data. Correlation analysis was performed 
by means of a Spearman correlation. Level of significance 
was established at α = 0.05. Graph pad prism 5.0 (Graph Pad 
Software, USA) and SPSS v. 18 (Microsoft, USA) were used for 
the analysis of the data.
resUlTs
The analysis of gene expression of the type I IFN pathway has 
been associated with increased inflammatory responses in other 
autoimmune disease such as SLE. There is limited information 
regarding the role of the transcriptional pathway and the relation-
ship that this might have with the inflammatory response in RA 
in the early stages of the disease and in the high-risk ACPA+ 
individuals. Therefore, we evaluated the gene expression of 
several genes associated with the IFN signature in the Mexican 
population. Given that several genes regulated by type I IFN can 
be grouped into several functions, such differences are described 
below. No differences in gender proportions were identified, and 
all patients belonged to a Mexican Mestizo population, which 
was not characterized for the presence of HLA-risk Alleles. All 
patients were treated (in case of RA patients) with DMARD, and 
methotrexate was used most frequently.
antiviral response genes of the iFn 
signature are Overexpressed in ra
An increased expression of the MXA mRNA was found when 
comparing the established RA (cRA) group with the high-risk 
group (ACPA+) and also with the control groups (both ACPA− 
and HC) as shown in Figure 1A (P < 0.05). No differences in gene 
expression were found for the eRA group in any comparison for 
this gene. MXB, another gene, involved in the antiviral response 
mediated by the type I IFN response was also found to have an 
increased expression when compared with the control groups (HC 
and ACPA−) and with the ACPA+ group (Figure 1B, P < 0.05), 
and the same pattern of increase across groups is observed as in 
MXA.
Transcriptional regulators of iFn 
signature are Overexpressed in 
established ra
IFIT1 gene expression was evaluated in the samples of the previ-
ously described groups. Significant differences were identified 
when comparing cRA with ACPA− individuals (Figure  2A, 
P < 0.05). Similar observations can be made for the IFIT2 gene 
FigUre 1 | analysis of gene expression associated with antiviral response. Gene expression analysis was carried out in cDNA synthesized from blood total 
RNA to assess the relative gene expression profile of type I interferon-related genes: (a) MXA and (B) MXB genes were analyzed. HC, healthy controls (n = 20); 
ACPA−, first-degree relatives of rheumatoid arthritis (RA) patients negative to anticitrullinated peptide antibodies (n = 20); ACPA+, first-degree relatives of RA 
patients positive to anticitrullinated peptide antibodies (n = 20); eRA, early RA patients (n = 10); cRA, chronic RA patients (n = 20). The graphs depict median ± IQR 
as descriptive statistics. Multiple comparisons tests were made by means of the non-parametric Kruskal–Wallis test. P values of less than 0.05 were considered 
statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
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that belongs to the same family of transcriptional regulators; 
significant differences were identified for this gene between the 
cRA and both the ACPA and HC groups (Figure 2B, P < 0.05).
Overexpression in established ra of the 
Proteasomal Degradation Machinery of 
the iFn signature
Regulation of protein degradation is a hallmark of the type I 
IFN signature, and given their role in antigen presentation by 
class I molecules of due to cross-priming, the expression of the 
“ISGlation” machinery of proteasomal degradation was also 
evaluated. Significant differences in gene expression were found 
for both the ISG15 and the HERC5 mRNAs when comparing the 
established disease patients with HC (Figures 3A,B, respectively). 
Also, a tendency toward the increase is observed in the natural 
history of the disease.
increased expression of Proliferation 
regulators of the iFn signature in ra 
Patients
Proliferation and expansion of B  cells is of major importance 
in inflammatory autoimmune diseases due to the generation of 
pathogenic antibodies. Given that several genes of the IFN signa-
ture pathway are associated with the regulation of proliferation in 
B cells, we sought to evaluate the expression of such genes in this 
phenomenon. Ly6E expression showed significant differences 
between established RA (cRA) and the ACPA− first-degree rela-
tives and HC as shown in Figure 4A (P < 0.05). Also, RSAD2 
has been shown to have similar functions, participating in the 
control of expansion of several immune cells (44). Significant 
differences were identified when comparing not only established 
RA (cRA) with HC but also the ACPA+ with HC, suggesting 
their involvement in early preclinical features of the disease and 
in the established inflammatory milieu of arthritis (Figure 4B, 
P < 0.05).
IFI6, IFI35, and EPSTRI1 gene expression 
is increased in ra
Other genes of the IFN signature such as IFI6 have been associ-
ated with apoptosis regulation (IFI6 and IFI35), epithelial to 
mesenchymal transition (EPSTRI1), and other functions. There 
is an increase in the EPSTRI1 gene expression in the cRA group 
compared to HC (Figure  5A, P <  0.05). No differences were 
found for IFI44L gene expression for any of the groups analyzed 
(Figure  5B, P >  0.05). A significant higher expression of IFI6 
was observed in the eRA group compared to ACPA− individu-
als and HC (Figure 5C, P < 0.05). IFI35 also showed significant 
differences in the cRA group when compared to HC (Figure 5D, 
P < 0.05).
autoantibodies against carbamylated and 
citrullinated Proteins correlate with the 
expression levels of several Type i  
iFn-regulated genes
Given the importance of several of the abovementioned genes 
in the regulation of proliferation of immune cells, as well as in 
the response in the antiviral response and (indirectly) in antigen 
presentation and consequently in the generation of antibodies by 
FigUre 3 | interferon (iFn)-1 signature genes associated with induction of proteasomal degradation. Gene expression analysis was carried out in cDNA 
synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related genes: (a) ISG15 and (B) HERC5 genes were analyzed. HC, 
healthy controls (n = 20); ACPA−, first-degree relatives of rheumatoid arthritis (RA) patients negative to anticitrullinated peptide antibodies (n = 20); ACPA+, 
first-degree relatives of RA patients positive to anticitrullinated peptide antibodies (n = 20); eRA, early RA patients (n = 10); cRA, chronic RA patients (n = 20). The 
graphs depict median ± IQR as descriptive statistics. Multiple comparisons tests were made by means of the non-parametric Kruskal–Wallis test. P values of less 
than 0.05 were considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
FigUre 2 | gene expression of the posttranscriptional regulators IFIT1 and IFIT2. Gene expression analysis was carried out in cDNA synthesized from 
blood total RNA to assess the relative gene expression profile of type I interferon-related genes: (a) IFIT1 and (B) IFIT2 genes were analyzed. HC, healthy controls 
(n = 20); ACPA−, first-degree relatives of rheumatoid arthritis (RA) patients negative to anticitrullinated peptide antibodies (n = 20); ACPA+, first-degree relatives of 
RA patients positive to anticitrullinated peptide antibodies (n = 20); eRA, early RA patients (n = 10); cRA, chronic RA patients (n = 20). The graphs depict 
median ± IQR as descriptive statistics. Multiple comparisons tests were made by means of the non-parametric Kruskal–Wallis test. P values of less than 0.05 were 
considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
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differentiation of B cells into plasmatic antibody-secreting cells, 
we wondered whether autoantibody levels might be associated 
with the gene expression of the IFN signature. After a non-par-
ametric Spearman correlation analysis, we identified significant 
correlations with the levels of anti-CarP antibodies for IFI6, IFI35, 
ISG15, Ly6E, and MXA (Spearman r, 0.249–0.352, P <  0.05; 
Table 2). In addition, significant correlations were identified for 
8 of the 12 IFN signature genes (IFI6, IFIT2, IFI35, ISG15, MXB, 
Ly6E, EPSTRI1, and MXA; Spearman r, 0.227–0.476, P < 0.05), 
suggesting an important participation of the gene regulation 
FigUre 4 | analysis of gene expression of the interferon (iFn)-1 signature associated with increased proliferation. Gene expression analysis was carried 
out in cDNA synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related genes: (a) Ly6E and (B) RSAD2 genes were 
analyzed. HC, healthy controls (n = 20); ACPA−, first-degree relatives of rheumatoid arthritis (RA) patients negative to anticitrullinated peptide antibodies (n = 20); 
ACPA+, first-degree relatives of RA patients positive to anticitrullinated peptide antibodies (n = 20); eRA, early RA patients (n = 10); cRA, chronic RA patients 
(n = 20). The graphs depict median ± IQR as descriptive statistics. Multiple comparisons tests were made by means of the non-parametric Kruskal–Wallis test.  
P values of less than 0.05 were considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
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mediated by the IFN signature in autoantibody generation. Also 
a trend for the increase of both anti-CarP and ACPA is observed 
when comparing for the natural history of the disease (data not 
shown).
DiscUssiOn
Rheumatoid arthritis is an inflammatory disease that is character-
ized by the generation of autoreactive clones of T and B cells and, 
in consequence, by the generation of autoantibodies (45). It has 
been proposed that autoantibodies could be involved in the gen-
eration of IFN through the activation of the pDC, and it could be 
implicated in the perpetuation of the inflammatory process as has 
been previously described for LES (46, 47). The first report that 
linked the IFN signature with autoimmunity in RA came from 
Van der Paw; he found an elevation in the expression pattern 
of several of the genes of the pathway in the established disease 
(25). However, little has been done to try to replicate such data 
in other populations and settings. Here, we report the analysis 
of several genes of the type I IFN signature and its relationship 
with high-risk individuals (ACPA+), eRA, and established RA 
and the participation of such genes in the physiopathology of the 
disease in different stages and their possible use as biomarkers in 
early stages of disease. Also, we discuss the association between 
the presence of anti-CarP and ACPA and the potential role of the 
type I IFN signature genes in the generation of such antibodies.
It has been reported that some chronic viral infections might 
be the trigger or at least are associated with, of autoimmunity, in 
particular due to cross-reactivity, as has been observed in several 
tropical viral infections such as Chikungunya (48), Epstein-Barr 
(49), and Zika (50), which have been associated with acute 
arthritis of unknown origin and have been poorly characterized 
(51, 52). In this regard, several genes of the IFN signature such as 
MXA and MXB have been associated with protection against viral 
infection (53, 54). Our data clearly show an increased expression 
of the MXA and MXB genes providing evidence of the role that 
these molecules might have in the induction of inflammation in 
the early phases of RA or even previous to the onset of symptoms 
in individuals at high risk, with the possible involvement of such 
molecules even in the preclinical autoimmune phase of RA, 
explaining just in part the lack of differences in the established 
phase of the disease. The risk of developing RA associated with 
increased expression of these genes needs to be further evaluated 
in the light of the induction of tolerance processes and determine 
whether MXA and MXB gene expression increase is due to viral 
infection and/or the generation of interferogenic complexes.
Recently, a strong association between RA and the unfolded 
protein response (UPR) was described (55–57), and therefore, 
the regulation of the transcription/translation process has been 
put on the spotlight of RA pathogenesis. It has been described 
that several regulators of the translation of proteins particularly 
GADD34 are associated with the UPR in RA (55); however, little 
attention has been put to the transcriptional process and their 
regulators such as IFIT1 and IFIT2 that are known to regulate 
the apoptotic process (58). In this regard, we found an increased 
expression of these genes in the established disease phase. 
Suggesting that the role of the transcriptional regulation in the 
chronic phase of RA might be associated with the activation of the 
FigUre 5 | genes associated with miscellaneous functions in the interferon (iFn)-1 signature. Gene expression analysis was carried out in cDNA 
synthesized from blood total RNA to assess the relative gene expression profile of type I IFN-related genes: (a) EPSTRLI1, (B) IFI44L, (c) IFI6, and (D) IFI35 genes 
were analyzed. HC, healthy controls (n = 20); ACPA−, first-degree relatives of rheumatoid arthritis (RA) patients negative to anticitrullinated peptide antibodies 
(n = 20); ACPA+, first-degree relatives of RA patients positive to anticitrullinated peptide antibodies (n = 20); eRA, early RA patients (n = 10); cRA, chronic RA 
patients (n = 20). The graphs depict median ± IQR as descriptive statistics. Multiple comparisons tests were made by means of the non-parametric Kruskal–Wallis 
test. P values of less than 0.05 were considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
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immune response by type I IFN; also, given that due to medica-
tion several viral infections become recurrent in these patients 
(59), upregulation of IFIT1 and IFIT2 could be associated with 
these infections in RA. Also the role of other regulators in the 
expression of these genes such as miRNA needs to be further 
evaluated, and also the viral subclinical infection status of such 
individuals (Epstein-Barr virus and cytomegalovirus infection 
status) needs to be determined.
The mechanisms of ubiquitination are very important for 
the clearance of several proteins within the cell and therefore 
are related to the UPR (60). ISG15 is a small ubiquitin molecule 
associated with antiviral response in a process called “ISGlation” 
(61). It has been described that this molecule can regulate the 
activity of negative regulator IRF3 and in this way promotes the 
expression of genes of the IFN signature (62). Further research 
on the role of HERC5 and ISG15 in RA pathogenesis is needed to 
establish their participation in experimental models of RA and to 
evaluate how is regulated in the early phases of disease or if the 
phenomenon is exclusively associated with chronic inflammatory 
processes as observed in the established disease patients. Also, the 
potential use of these molecules as markers of treatment success 
has been described previously by Raterman and colleagues (63).
The regulation of apoptosis may also play an important role in 
the pathogenesis of RA (13). Little is known about the function 
of IFI6, and it has been described that IFI6 inhibits apoptosis 
trough the downregulation of caspase 3 and casase 9 (64). This 
TaBle 2 | correlation analyses of autoantibody levels [anticitrullinated protein antibodies (acPa) and anticarbamylated protein (anti-carP) antibodies] 
with relative expression of interferon-1 signature genes.
relative expression
iFi44l IFI6 IFIT1 IFIT2 IFI35 ISG15 MXB ly6e rsaD2 HERC5 EPSTRI1 MXA
Anti-CarP 0.111 0.249* 0.187 0.101 0.288* 0.294* 0.226 0.264* 0.161 0.197 0.125 0.352**
0.383 0.047 0.139 0.425 0.021 0.018 0.072 0.035 0.203 0.118 0.327 0.004
64 64 64 64 64 64 64 64 64 64 64 64
ACPA 0.33 0.261* 0.146 0.417*** 0.438*** 0.476*** 0.273** 0.227* −0.121 0.188 0.444*** 0.287**
0.750 0.011 0.158 0.000 0.000 0.000 0.007 0.027 0.241 0.067 0.000 0.005
95 95 95 95 95 95 95 95 95 95 95 95
Data are presented as follows: correlation coefficient, two-tailed P value, and N.
Spearman correlation analysis was carried out.
P values of <0.05 were considered significant (*P < 0.05; **P < 0.01; ***P < 0.001).
D’Agostino-Pearson normality test was carried out for the assumption of normality of the data.
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effect might be associated with increased survival of inflamma-
tory cells that perpetuate the activation of antibody-producing 
B cells, and this needs to be further evaluated. Also, Ly6E has 
been associated with an increased proliferation in several cell 
lineages (65) and could mediate the process of B  cell expan-
sion in inflammatory disorders through a TGF-beta-mediated 
mechanism, but this needs to be further explored. RSAD2 (also 
known as Viperin) is an antiviral protein associated with regula-
tion of proliferation of immune cells, and it has been associated 
with Th2 polarization of immune cells through a mechanism 
mediated by GATA3, NF-κB, and IL-4 production, therefore 
inducing and modulating the production of autoantibodies 
(44). The increased expression of RSAD2 in ACPA+ individuals 
and cRA patients might contribute to autoantibody generation. 
The increased expression of this pathway needs to be further 
elucidated given that expression of these molecules is mainly 
regulated by viral infection (66–68).
There is no clear evidence if the perpetuation of the inflamma-
tory process through the activation of inflammatory cells might 
be associated with increased levels of antibodies in several stages 
of the disease (69, 70). For this purpose, we analyzed the expres-
sion of several genes of the type IFN gene signature in groups of 
individuals who had no previous family history of the disease, 
HC, and also in individuals with ACPA−, ACPA+, eRA, and 
cRA, which accounts for the natural history of the disease. We 
found a significant correlation between the expression of these 
genes associated with proliferation control of B cell maturation 
and antibody production such as IFI6, IFI35, ISG15, EPSTRI1, 
MXA, and Ly6E, several of which are associated with promo-
tion of B cell differentiation and antibody production (71). Our 
results differ from those of other groups in which no association 
has been found for autoantibody production of ACPA and other 
autoantibodies (RF, antinucleosome, etc.) in adalimumab-treated 
patients (72), which has been recently confirmed to modify the 
gene expression pattern of the type I IFN signature in neutrophils 
of patients with RA (73). Also the authors did not analyze the 
correlation effect of the IFN signature gene expression on the 
antibodies that were analyzed, neither did they analyze the anti-
CarP antibodies. Another substantial difference that may account 
for the differences in our findings and that of Cantaert et al is that 
we included individuals (eRA) who were virgin to treatment (72). 
Our groups of individuals were recruited in an attempt to emulate 
the natural history of disease in a patient with RA, and therefore, 
the tendency is clear to increase the levels of autoantibodies in the 
late phases of disease. Ethnic and population differences may also 
account for such differences (74, 75).
Although our correlation analysis cannot be confirmed as cau-
sality, it clearly highlights the association of the increased expres-
sion of Type I IFN response genes with the master regulators of 
B cell development, and differentiation into plasma cells might 
be of pivotal importance in the generation of autoantibodies in 
RA, which has been already described in SLE (76) and some myo-
pathies (77). Further mechanistic studies are needed to confirm 
such association and describe the detailed mechanism.
This article provides evidence of the limited use of the gene 
expression of these markers to differentiate the early stages of RA, 
although MXA, MXB, and IFI6 showed an increased expression 
when compared to HC. The participation of several genes of the 
IFN signature is also described in the context of the available data 
on the pathogenesis of the disease. We describe a plausible link 
between type I IFN-induced gene expression and the generation 
of anti-CarP antibodies and ACPA. Limitations of the study 
include sample size and previous DMARD use in the cRA group.
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